YR 007
Alternative Names: YR-007Latest Information Update: 24 Feb 2023
At a glance
- Originator YIRUI Pharmaceutical Technology
- Class Antipruritics; Small molecules
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pruritus
Most Recent Events
- 17 Feb 2023 Preclinical trials in Skin disorders in China (unspecified route) (Yirui Pharmaceutical Technology pipeline, February 2023)
- 17 Feb 2023 Yirui Pharmaceutical Technology announces intention to submit NDA for Pruritus in 2028 (Yirui Pharmaceutical Technology pipeline, February 2023)
- 17 Feb 2023 Yirui Pharmaceutical Technology announces intention to submit lND application for Pruritus in H2 2023 (Yirui Pharmaceutical Technology pipeline, February 2023)